Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialAchim Rittmeyer, David R. Gandara, Fabrice Barlési et al.|The Lancet|2016Cited by 4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerGiorgio V. Scagliotti, David R. Gandara, Purvish Parikh et al.|Journal of Clinical Oncology|2008Cited by 3.2k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyNasser H. Hanna, Paul A. Bunn, Thomas Müller et al.|Journal of Clinical Oncology|2004Cited by 2.4k
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Nick Thatcher, Kevin Carroll, Alex Y. Chang et al.|The Lancet|2005Cited by 2.1k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1Giuseppe Giaccone, David H. Johnson, Roy S. Herbst et al.|Journal of Clinical Oncology|2004Cited by 1.7k